drugset / Trial / NCT02433236
Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Phase 2, multi-center, open label extension study to evaluate 2 dose regimens of fostamatinib in approximately 25 subjects. The study will consist of 11 visits over 15 months.
Timeline
- Start
- 2015-09
- Primary completion
- 2015-09
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fostamatinib | Small molecule | 100 mg | Oral |
| Subject | Fostamatinib | Small molecule | 150 mg | Oral |